SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VISX
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: ajs who wrote (476)3/30/1998 4:36:00 PM
From: Jim Mac  Read Replies (1) of 1754
 
Summit tried many years ago to find a way around Visx patents. They failed. Why? Because Visx's patent rights are SOLID.

Summit's failure to find a weakness in Visx's position contributed to Summit agreeing to form Pillar Point Partners.

If Summit, a tenacious competitor, couldn't find a way to undermine Visx's patent position, then who can?

NO ONE CAN. NO ONE WILL.

And NO ONE can stop Visx from collecting procedure fees on its lasers, which are the most productive in U.S. FTC itself, told Visx many months ago it had no problem with that.

Misinformed speculators (shorts) are living dangerously. Informed investors are accumulating VISX. Just look at last week's buying/covering binge and the support VISX has in the mid-20's.

When 98Q1 earnings are released in a couple weeks, and FTC meeting leads to no more than a dismissal of complaint or a rumble date a year hence, VISX will blow through $35.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News